Report
EUR 93.41
For Business Accounts Only
NH Health provides cancer screen kits for convenient early screening targeting populations recommended for regular cancer screening.
The company's approved product ColoClear has an impressive accuracy compared with peer products for colorectal cancer. In addition to the ColoClear, it also offered a more mass-market product, Pupu Tube for home-based testing.
The company's product has a huge unmet market and a high barrier to entry. We believe its uniqueness as the only investable stock in the segment will make the deal interesting to investors.
The company's management has a good working experience and is backed by a strong line up of international and domestic investors.
New Horizon Health (诺辉健康) Pre-IPO - A hot medical device deal in making
New Horizon Health, a pioneer in the colorectal cancer screening market in China, is looking to raise up to USD 300m to list via a Hong Kong listing.NH Health provides cancer screen kits for convenient early screening targeting populations recommended for regular cancer screening.
The company's approved product ColoClear has an impressive accuracy compared with peer products for colorectal cancer. In addition to the ColoClear, it also offered a more mass-market product, Pupu Tube for home-based testing.
The company's product has a huge unmet market and a high barrier to entry. We believe its uniqueness as the only investable stock in the segment will make the deal interesting to investors.
The company's management has a good working experience and is backed by a strong line up of international and domestic investors.
Underlying
New Horizon Health
Provider
Aequitas Research
Aequitas Research is a leading ECM research firm with a focus on IPOs and placements/follow-on offerings across the Asia Pacific with deal size of over USD100m.
Since 2015, we have covered 400+ IPOs and 450+ placements with a hit rate of 73% and 65%, respectively. We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic analysis.
Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis. We also provide a more quant driven analysis on placement/follow-on offerings.
Markets that we cover include:
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.
Ke Yan
Other Reports on these Companies
Other Reports from Aequitas Research
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.